OCIAD2

Across TCGA pan-cancer cohorts, OCIAD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OCIAD2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher OCIAD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated OCIAD2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where OCIAD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.491	0.808	.010	21	view →
HNSC	DFS	Quartile	III,IV	0.987	0.687	.007	19	view →
LUAD	OS	Median	All	0.650	1.000	.002	16	view →
CCRCC	DFS	Quartile	All	0.697	0.956	.008	11	view →
GBM	DFS	Quartile	All	0.216	0.423	.002	11	view →
PDAC	OS	Tertile	III,IV	1.000	0.527	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OCIAD2–LSCC (DFS)

Open the LSCC breakdown →